Sarepta Therapeutics, Inc. (SRPT) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2024
Loading P/E history...
SRPT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Sarepta Therapeutics, Inc. (SRPT) trades at a price-to-earnings ratio of -3.2x, with a stock price of $23.03 and trailing twelve-month earnings per share of $0.53.
The current P/E is 101% below its 5-year average of 598.1x. Over the past five years, SRPT's P/E has ranged from a low of 53.6x to a high of 1849.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, SRPT trades at a 115% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, SRPT trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SRPT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SRPT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $11B | 30.3Lowest | -Best | -19% | |
| $40B | 130.0 | -Best | +207%Best | |
| $9B | 42.2 | -Best | +128% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SRPT Historical P/E Data (2024–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $121.59 | $2.27 | 53.6x | -91% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $124.89 | $1.20 | 104.1x | -83% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $158.00 | $0.41 | 385.4x | -36% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $129.46 | $0.07 | 1849.4x | +209% |
Average P/E for displayed period: 598.1x
See SRPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SRPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SRPT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSRPT — Frequently Asked Questions
Quick answers to the most common questions about buying SRPT stock.
Is SRPT stock overvalued or undervalued?
SRPT trades at -3.2x P/E, below its 5-year average of 598.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SRPT's valuation compare to peers?
Sarepta Therapeutics, Inc. P/E of -3.2x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is SRPT's PEG ratio?
SRPT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2024.